Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the Cowen 43rd Annual Health Care...
February 21, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

—ORLADEYO net revenue of $70.7 million for Q4 2022 and $251.6 million for FY 2022— —ORLADEYO net revenue in 2023 expected to be no less than $320 million— —ORLADEYO peak sales expected to be $1...
February 07, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

RESEARCH TRIANGLE PARK, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2022 financial results...
February 06, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
February 03, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral,...
January 26, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial...
January 23, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to...
January 09, 2023 07:05 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)— —ORLADEYO net revenue expected to be no less than $320 million in 2023— —Company expects ORLADEYO peak sales...
January 09, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE...
January 05, 2023 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...